The possibility of cancer immune editing in gliomas. A critical review

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

(2017) Kevin Bielamowicz et al.   NEURO-ONCOLOGY

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

(2017) Tiffany R. Hodges et al.   NEURO-ONCOLOGY

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy

(2017) Teresa Davoli et al.   SCIENCE

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

(2017) Kazuyoshi Takeda et al.   Nature Communications

CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells

(2016) Alan L. Chang et al.   CANCER RESEARCH

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency

(2016) Eric Bouffet et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

(2016) Deborah T. Blumenthal et al.   JOURNAL OF NEURO-ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Clonal evolution of glioblastoma under therapy

(2016) Jiguang Wang et al.   NATURE GENETICS

The role of microglia and macrophages in glioma maintenance and progression

(2016) Dolores Hambardzumyan et al.   NATURE NEUROSCIENCE

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

(2015) Sachet A Shukla et al.   NATURE BIOTECHNOLOGY

Mutational landscape and clonal architecture in grade II and III gliomas

(2015) Hiromichi Suzuki et al.   NATURE GENETICS

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The Transcriptional Regulatory Network of Proneural Glioma Determines the Genetic Alterations Selected during Tumor Progression

(2014) A. M. Sonabend et al.   CANCER RESEARCH

T Lymphocytes Restrain Spontaneous Metastases in Permanent Dormancy

(2014) I. Romero et al.   CANCER RESEARCH

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Extracranial glioblastoma in transplant recipients

(2014) Sopiko Jimsheleishvili et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hematogenous dissemination of glioblastoma multiforme

(2014) C. Muller et al.   Science Translational Medicine

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class

(2013) W. C. Rutledge et al.   CLINICAL CANCER RESEARCH

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

(2013) Ana B. del Campo et al.   INTERNATIONAL JOURNAL OF CANCER

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy

(2012) Valérie Dutoit et al.   BRAIN

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Expression of tumour-specific antigens underlies cancer immunoediting

(2012) Michel DuPage et al.   NATURE

An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

(2012) L. Senovilla et al.   SCIENCE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

(2011) B. P. Pollack et al.   CLINICAL CANCER RESEARCH

Glioblastoma Models Reveal the Connection between Adult Glial Progenitors and the Proneural Phenotype

(2011) Liang Lei et al.   PLoS One

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development

(2010) Nhu Nam Tran Thang et al.   CANCER RESEARCH

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

(2009) S. Yip et al.   CLINICAL CANCER RESEARCH

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

(2009) James F Curtin et al.   PLOS MEDICINE

Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy

(2008) Rafael Carretero et al.   IMMUNOGENETICS

Transmission of Glioblastoma Multiforme After Bilateral Lung Transplantation

(2008) Hongbin Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors

(2008) Joannes F.M. Jacobs et al.   NEURO-ONCOLOGY